Publications by authors named "M Moskovitz"
Purpose: To assess the attitudes of dentists in Israel to minimal intervention on primary teeth.
Methods: For this cross-sectional study, data were accessed from questionnaires that were completed anonymously by members of the Israeli Society of Paediatric Dentistry. For four clinical scenarios, the respondents were asked to describe the stage at which they would intervene, the type of preparation they would utilize, and the restorative materials they would use.
Background: Planning the extent of paediatric dental treatment under deep sedation is highly important, as the duration of the sedation should be limited to approximately 1 h, and the amount of local anesthesia is limited by the children's body weight.
Aim: To compare treatment plans estimated at initial examinations with actual dental treatments under intravenous deep sedation. We examined factors that could affect the differences.
Background: ABBV-184, a novel survivin peptide-targeting T-cell receptor (TCR)/anti-CD3 bispecific protein, demonstrated preclinical T-cell activation and cytotoxicity toward HLA-A2:01-positive tumor lines. This first-in-human trial evaluated ABBV-184 monotherapy in patients with acute myeloid leukemia (AML) and non-small cell lung cancer (NSCLC).
Research Design And Methods: This phase 1 multicenter, open-label, dose escalation trial (NCT04272203) enrolled adult patients with relapsed/refractory AML or NSCLC with an HLA-A2:01 restricted genotype.
Although comprehensive biomarker testing is recommended for all patients with advanced/metastatic non-small cell lung cancer (NSCLC) before initiation of first-line treatment, tissue availability can limit testing. Genomic testing in liquid biopsies can be utilized to overcome the inherent limitations of tissue sampling and identify the most appropriate biomarker-informed treatment option for patients. The Blood First Assay Screening Trial is a global, open-label, multicohort trial that evaluates the efficacy and safety of multiple therapies in patients with advanced/metastatic NSCLC and targetable alterations identified by liquid biopsy.
View Article and Find Full Text PDFArticle Synopsis
- A Phase III study tested the efficacy of subcutaneous versus intravenous amivantamab for patients with advanced non-small cell lung cancer (NSCLC) who had progression after prior treatments.
- Results showed that the subcutaneous form maintained efficacy, with fewer side effects and a significantly longer overall survival, while also being more convenient to administer.
- Patients receiving subcutaneous amivantamab had less infusion-related reactions and faster administration times, with 85% finding the treatment convenient compared to only 35% in the intravenous group.